Liat HAYARDENY;Iris GROSSMAN;Amir TCHELET;Michael HAYDEN;David LADKANI;Colin James Douglas ROSS
发明人:
Amir TCHELET,Michael HAYDEN,Liat HAYARDENY,Colin James Douglas ROSS,Iris GROSSMAN,David LADKANI
申请号：
US15410091
公开号：
US20180002753A1
申请日:
2017.01.19
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The present invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of:(i) determining a genotype of the subject at a location corresponding to the location of one or more single nucleotide polymorphisms (SNPs) selected from the group consisting of: Group 1,(ii) identifying the subject as a predicted responder to glatiramer acetate if the genotype of the subject contains one or more A alleles at the location of Group 2,one or more C alleles at the location of Group 3,one or more G alleles at the location of Group 4, orone or more T alleles at the location of kgp18432055, kgp279772, kgp3991733 or kgp7242489； and(iii) administering the pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier to the subject only if the subject is identified as a predicted responder to glatiramer acetate.
